Privia Health Group (NASDAQ:PRVA) Stock Price Expected to Rise, Canaccord Genuity Group Analyst Says

Privia Health Group (NASDAQ:PRVA) had its target price increased by stock analysts at Canaccord Genuity Group from $34.00 to $35.00 in a research report issued on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Canaccord Genuity Group’s price target would indicate a potential upside of 47.37% from the company’s previous close.

A number of other research analysts have also weighed in on PRVA. Wolfe Research set a $31.00 price objective on Privia Health Group in a report on Tuesday, January 6th. Citizens Jmp lifted their price objective on Privia Health Group from $30.00 to $31.00 and gave the stock a “market outperform” rating in a report on Friday, November 7th. Truist Financial reissued a “buy” rating and issued a $31.00 target price (up from $30.00) on shares of Privia Health Group in a report on Monday, November 10th. Stephens reissued an “overweight” rating and set a $32.00 price objective on shares of Privia Health Group in a research note on Thursday, December 4th. Finally, BMO Capital Markets initiated coverage on Privia Health Group in a report on Thursday, November 13th. They set an “outperform” rating and a $30.00 target price on the stock. Thirteen analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, Privia Health Group presently has an average rating of “Moderate Buy” and a consensus target price of $30.79.

Privia Health Group Price Performance

NASDAQ:PRVA opened at $23.75 on Friday. Privia Health Group has a 12 month low of $18.77 and a 12 month high of $26.51. The firm has a market capitalization of $2.92 billion, a PE ratio of 139.71, a price-to-earnings-growth ratio of 1.64 and a beta of 0.83. The business’s fifty day moving average price is $23.07 and its 200 day moving average price is $23.48.

Privia Health Group (NASDAQ:PRVA) last announced its quarterly earnings results on Thursday, February 26th. The company reported $0.25 earnings per share for the quarter, beating analysts’ consensus estimates of $0.04 by $0.21. Privia Health Group had a net margin of 1.08% and a return on equity of 3.12%. The firm had revenue of $541.17 million during the quarter, compared to analysts’ expectations of $516.61 million. During the same period in the previous year, the company earned $0.21 earnings per share. Privia Health Group’s quarterly revenue was up 17.4% compared to the same quarter last year. As a group, equities analysts anticipate that Privia Health Group will post 0.14 EPS for the current year.

Insiders Place Their Bets

In related news, Director Matthew Shawn Morris sold 13,647 shares of the company’s stock in a transaction on Friday, December 12th. The stock was sold at an average price of $25.01, for a total value of $341,311.47. Following the completion of the transaction, the director directly owned 68,188 shares in the company, valued at approximately $1,705,381.88. This represents a 16.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO David Mountcastle sold 23,887 shares of the stock in a transaction dated Friday, December 12th. The stock was sold at an average price of $25.03, for a total value of $597,891.61. Following the transaction, the chief financial officer owned 172,909 shares in the company, valued at $4,327,912.27. This trade represents a 12.14% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 10.70% of the company’s stock.

Institutional Trading of Privia Health Group

Several hedge funds and other institutional investors have recently added to or reduced their stakes in PRVA. Great Lakes Advisors LLC acquired a new position in shares of Privia Health Group in the 3rd quarter valued at $4,487,000. Advantage Alpha Capital Partners LP acquired a new stake in shares of Privia Health Group during the 2nd quarter worth $3,941,000. Hsbc Holdings PLC raised its position in shares of Privia Health Group by 69.2% in the 2nd quarter. Hsbc Holdings PLC now owns 113,718 shares of the company’s stock worth $2,549,000 after buying an additional 46,526 shares during the period. Edgestream Partners L.P. acquired a new position in Privia Health Group in the second quarter valued at $2,209,000. Finally, Bailard Inc. purchased a new stake in Privia Health Group during the second quarter valued at about $531,000. Hedge funds and other institutional investors own 94.48% of the company’s stock.

Key Privia Health Group News

Here are the key news stories impacting Privia Health Group this week:

• Positive Sentiment: Q4 and full‑year 2025 results beat expectations and management delivered bullish 2026 guidance — revenue, EPS and adjusted EBITDA came in above guidance with adjusted EBITDA up strongly Y/Y and management guiding ~20% adjusted EBITDA growth (midpoint) and expansion to 24 states. This is the main fundamental driver supporting upside. GlobeNewswire
• Positive Sentiment: Analyst optimism: Canaccord recently raised its PRVA price target (to $35) and the mean analyst target implies material upside; several outlets highlight a consensus uplift in price targets — supportive for further analyst‑driven buying. Canaccord / Benzinga coverage
• Positive Sentiment: Company guidance emphasizes converting ~80% of adjusted EBITDA to free cash flow and ending 2026 with ~ $600M cash, plus no debt — balance‑sheet strength that can underwrite organic growth or M&A. MSN / coverage of guidance
• Neutral Sentiment: Supporting disclosure and materials: transcript and slide deck from the earnings call are available for deeper read — useful for modeling cadence of revenue/EBITDA conversions and provider growth assumptions. Earnings transcript (Yahoo)
• Negative Sentiment: Offset risks: large non‑cash stock‑based compensation ($71.1M in 2025), management’s note that forward non‑GAAP measures aren’t reconciled to GAAP (adding forecasting uncertainty), and disclosure of insider sales in recent months — items that can temper investor enthusiasm. QuiverQuant / release summary
• Negative Sentiment: Valuation and market action: PRVA trades at a high trailing P/E and the stock is seeing elevated volume today — likely profit‑taking or rotation despite the beat. That dynamic, plus at least one lower analyst target in the mix historically, helps explain short‑term downward pressure.

Privia Health Group Company Profile

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.